GlassScriptPhysician profile
Rasvin Buttar
NPI 1104328152
$2,003.61
in general payments reported to CMS, 2019-2025
24 companies · $777 in 2025
The $777 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2023: $661 · 2024: $294 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.58 |
| Education | $123.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $354.84 | 2021-2025 | Rybrevant, Imbruvica, Darzalex |
| Novartis Pharmaceuticals Corporation | $268.88 | 2021-2025 | |
| Pfizer INC. | $140.37 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $127.47 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Eisai INC. | $112.43 | 2021-2025 | |
| Amgen INC. | $107.77 | 2021-2023 | Nplate, Vectibix, Kyprolis |
| Pharmacyclics LLC, An Abbvie Company | $99.89 | 2021-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $95.63 | 2023-2025 | |
| Celgene Corporation | $86.04 | 2023-2025 | Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $77.21 | 2023-2025 | Lynparza, Imfinzi |
| Lilly USA, LLC | $66.09 | 2023-2024 | Verzenio, Jaypirca |
| Mirati Therapeutics, INC. | $61.12 | 2023-2024 | Krazati |
| Genentech USA, INC. | $52.64 | 2023-2025 | Polivy, Tecentriq |
| Incyte Corporation | $51.32 | 2025 | Jakafi, Monjuvi |
| Kite Pharma, INC. | $45.51 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39.36 | 2025 | Opdivo |
| Napo Pharmaceuticals INC | $36.42 | 2025 | Gelclair Concentrated Oral Gel |
| Seagen INC. | $30.93 | 2023 | Padcev |
| Nuvation Bio INC. | $30.80 | 2025 | Ibtrozi |
| Iovance Biotherapeutics, INC. | $27.64 | 2025 | Amtagvi |
| Sobi, INC | $25.94 | 2023 | |
| Morphosys, US INC. | $23.43 | 2023 | Monjuvi |
| Clovis Oncology, INC. | $21.05 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasvin Buttar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.